Doctors are beginning to notice Covid-19 cases that look more like a very bad cold, especially in areas of the country where the highly contagious delta variant is quickly spreading.
ZVIMBA, Zimbabwe (AP) — For Pelagia Bvukura, who lives in a rural part of north-central Zimbabwe, COVID-19 had always been a “city disease,” affecting those in the capital, Harare, or other, distant big towns.
MOSCOW (Reuters) -Russia’s Sputnik V vaccine against COVID-19 is around 90% effective against the highly contagious Delta variant of coronavirus, its developers said on Tuesday.
Three scientific studies released on Monday offered fresh evidence that widely used vaccines will continue to protect people against the coronavirus for long periods, possibly for years, and can be adapted to fortify the immune system still further if needed.
Most people immunized with the mRNA vaccines may not need boosters, one study found, so long as the virus and its variants do not evolve much beyond their current forms — which is not guaranteed. Mix-and-match vaccination shows promise, a second study found, and booster shots of one widely used vaccine, if they are required, greatly enhance immunity, according to a third report.
A mixed schedule of vaccines where a shot of Pfizer's Covid-19 vaccine is given four weeks after an AstraZeneca shot will produce better immune responses than giving another dose of AstraZeneca, an Oxford study said on Monday.
The vaccines made by Pfizer-BioNTech and Moderna set off a persistent immune reaction in the body that may protect against the coronavirus for years, scientists reported on Monday.
The findings add to growing evidence that most people immunized with the mRNA vaccines may not need boosters, so long as the virus and its variants do not evolve much beyond their current forms — which is not guaranteed. People who recovered from Covid-19 before being vaccinated may not need boosters even if the virus does make a significant transformation.
“It’s a good sign for how durable our immunity is from this vaccine,” said Ali Ellebedy, an immunologist at Washington University in St. Louis who led the study, which was published in the journal Nature.
The study did not consider the vaccine made by Johnson & Johnson, but Dr. Ellebedy said he expected the immune response to be less durable than that produced by mRNA vaccines.
Recent Comments